Sanofi 'Fine-Tuning' Cialis OTC Switch Application
This article was originally published in The Pink Sheet
Executive Summary
Potential Cialis switch and the pending addition of Boehringer Ingelheim's consumer business are the revenue drivers highlighted by company execs on earnings call; second-quarter consumer health product revenues slipped 4.3% to $886.4m as a mild allergy season in the US and economic chaos in Venezuela drag down sales.